Raymond Debbane Portfolio
Invests via Siren, L.L.C. | Managed by Raymond Debbane
Invests via Siren, L.L.C.
Managed by Raymond Debbane
Automatically Tracked
Raymond Debbane Profile
Seasoned technology and fintech investor and operator, Raymond Debbane is focused on growth-stage software, payments and digital services. He combines operating experience leading cross-functional teams with investment-oriented portfolio construction, active board involvement, and strategic M&A support to drive scaling and exit value. Investment style emphasizes product-market fit, unit economics, and repeatable revenue models. Background blends technical and commercial disciplines and a track record of partnering with founders to professionalize operations and drive capital-efficient growth.
Seasoned technology and fintech investor and operator, Raymond Debbane is focused on growth-stage software, payments and digital services. He combines operating experience leading cross-functional teams with investment-oriented portfolio construction, active board involvement, and strategic M&A support to drive scaling and exit value. Investment style emphasizes product-market fit, unit economics, and repeatable revenue models. Background blends technical and commercial disciplines and a track record of partnering with founders to professionalize operations and drive capital-efficient growth.
Investment Philosophy & Strategy
Focuses on growth-stage software, payments and digital services with a bias toward businesses demonstrating clear product-market fit, repeatable revenue and strong unit economics. Allocates capital to companies where operational improvements and go-to-market rigor can materially accelerate scale; prefers active minority or board-backed positions to influence strategy, metrics and M&A timing. Investment horizon targets multi-year value creation through capital-efficient growth, disciplined downside protection, founder partnership and pragmatic exit planning.
Focuses on growth-stage software, payments and digital services with a bias toward businesses demonstrating clear product-market fit, repeatable revenue and strong unit economics. Allocates capital to companies where operational improvements and go-to-market rigor can materially accelerate scale; prefers active minority or board-backed positions to influence strategy, metrics and M&A timing. Investment horizon targets multi-year value creation through capital-efficient growth, disciplined downside protection, founder partnership and pragmatic exit planning.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
36.85%
Gain -0.09%
Monthly
1.54%
Yearly
20.21%
Drawdown
48.09%
$3.53B
Equity
Holdings
$3.53B
Investment
$2.52B
$1.24B
Profit -$3.75M
Realized
$229.61M
Unrealized
$1.01B
Dividends
$620,555.79
Goals
Avg. 26.5% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
-0.09%
Profit
-$3.75M
Win %
57%
This Week
Compared To Last Week
Gain
-0.1%
Profit
-$3.75M
Win %
57%
This Month
Compared to last month
Gain
-0.25%
Profit
-$9.18M
Win %
57%
This Year
Compared to last year
Gain
-9.45%
Profit
-$287.65M
Win %
59%
ELVN Enliven Therapeutics, Inc.
+14.3%
+$4.31M 
KRRO Korro Bio Inc.
+10.26%
+$375,535.44 
RAPP Rapport Therapeutics Inc.
+9.06%
+$2.05M 
TENX Tenax Therapeutics Inc.
+6.99%
+$320,355.75 
AEVA Aeva Technologies, Inc.
+5.87%
+$151,800 
ORIC Oric Pharmaceuticals Inc.
+5.75%
+$1.35M 
SEPN Septarna Inc.
+5.64%
+$3.84M 
TRVI Trevi Therapeutics Inc.
+5.57%
+$1.34M 
CGEM Cullinan Therapeutics, Inc.
+5.55%
+$859,255.2 
IREN IREN Limited
+5.4%
+$131,886 
DBVT Dbv Technologies S.A. Sponsored ADR
+5.29%
+$1.63M 
AMLX Amylyx Pharmaceuticals, Inc. Common Stock
+4.89%
+$836,400 
ABSI Absci Corporation
+4.46%
+$522,000 
KYMR Kymera Therapeutics Inc.
+3.91%
+$10.34M 
TNGX Tango Therapeutics Inc.
+3.76%
+$6.34M 
VTVT vTv Therapeutics Inc.
+3.72%
+$191,525 
RZLT Rezolute, Inc.
+3.63%
+$465,960.18 
ZURA Zura Bio Ltd.
+3.35%
+$448,183.92 
DNLI Denali Therapeutics Inc.
+3.04%
+$893,768.32 
BEKE Ke Holdings Inc. ADR
+2.99%
+$49,000 
FHTX Foghorn Therapeutics Inc.
+2.96%
+$86,486.4 
CRNX Crinetics Pharmaceuticals Inc.
+2.8%
+$1.79M 
QURE uniQure N.V.
+2.8%
+$750,000 
DFTX Definium Therapeutics, Inc.
+2.65%
+$588,475.52 
EWTX Edgewise Therapeutics, Inc.
+2.65%
+$3.99M 
PRMB Primo Brands Corp. Common Stock
+2.59%
+$30,500 
WHWK Whitehawk Therapeutics, Inc.
+2.46%
+$208,200 
TSHA Taysha Gene Therapies Inc.
+2.33%
+$1.15M 
PVLA Pavella Therapeutics Inc.
+2.28%
+$625,688.55 
RCUS Arcus Biosciences Inc.
+2.15%
+$1.5M 
BCAX Bicara Therapeutics Inc.
+1.93%
+$2.38M 
TSLA Tesla, Inc.
+1.82%
+$156,520 
MANE Veradermics Inc.
+1.77%
+$2.51M 
ONC BeOne Medicines, Ltd. American Depositary Receipt
+1.62%
+$1.96M 
LXRX Lexicon Pharmaceuticals, Inc.
+1.59%
+$1.33M 
STOK Stoke Therapeutics Inc.
+1.57%
+$917,859.62 
RELY Remitly Global, Inc.
+1.54%
+$447,548.59 
COGT Cogent Biosciences, Inc.
+1.47%
+$820,450.5 
FPS Forgent Power Solutions, Inc.
+1.41%
+$81,999.9 
NBP NovaBridge Biosciences American Depositary Shares
+1.36%
+$60,000 
DYN Dyne Therapeutics Inc.
+1.34%
+$534,990 
CYTK Cytokinetics, Incorporated
+1.27%
+$540,277.76 
OLMA Olema Pharmaceuticals Inc.
+1.23%
+$570,833.88 
SEER Seer, Inc.
+1.18%
+$49,173.46 
MNPR Monopar Therapeutics Inc.
+1.14%
+$182,329.38 
WVE Wave Life Sciences Ltd.
+1.03%
+$147,000 
CTMX CytomX Therapeutics Inc.
+1.01%
+$103,731.33 
DT Dynatrace, Inc.
+0.94%
+$57,000 
NU Nu Holdings Ltd.
+0.83%
+$2,500 
RYTM Rhythm Pharmaceuticals Inc.
+0.82%
+$522,367.92 
TSM Taiwan Semiconductor Manufacturing Co. Ltd. ADR
+0.68%
+$120,691.28 
GOOGL Alphabet Inc
+0.53%
+$125,492.73 
PDD PDD Holdings Inc. American Depositary Shares
+0.32%
+$21,684.26 
ERAS Erasca, Inc.
+0.29%
+$449,769.84 
ANNX Annexon, Inc.
+0.21%
+$39,586.46 
TBLA Taboola.com Ltd.
+0.21%
+$99,694.95 
NVDA NVIDIA Corporation
+0.16%
+$28,507.2 
SLN Silence Therapeutics plc ADR
+0.15%
+$29,114.38 
MSFT Microsoft Corp.
+0.1%
+$16,551.59 
SYRE Spyre Therapeutics, Inc.
+0.03%
+$16,371.96 
ARWR
0%
$0 
CLBT Cellebrite DI Ltd.
0%
$0 
GLTO Galecto Inc.
0%
$0 
IKT Inhibikase Therapeutics Inc.
0%
$0 
NMRA Neumora Therapeutics, Inc.
0%
$0 
RVMDW Revolution Medicines, Inc. Warrant
0%
$0 
YNDX Yandex NV
0%
$0 
MPLT MapLight Therapeutics, Inc.
-8.57%
-$1.17M 
GOSS Gossamer Bio Inc.
-8.47%
-$78,134.52 
IVVD Invivyd Inc.
-5.29%
-$172,000.16 
RANI Rani Therapeutics Holdings Inc.
-5.24%
-$84,000 
GENB Generate Biomedicines, Inc.
-4.25%
-$404,857.2 
FIG Figma Inc. Class A Common Stock
-4.21%
-$40,750 
FULC Fulcrum Therapeutics Inc.
-2.82%
-$235,000 
AGMB Agomab Therapeutics NV
-2.73%
-$111,037.5 
AGEN Agenus Inc.
-2.65%
-$95,782.5 
MSLE Satellos Bioscience Inc.
-2.54%
-$133,811.1 
MNDY monday.com Ltd.
-2.53%
-$50,250 
GTLB GitLab Inc.
-2.15%
-$61,000 
DDOG Datadog, Inc. Class A Common Stock
-1.85%
-$235,663.09 
MU Micron Technology, Inc.
-1.43%
-$85,560.06 
MDLN Medline Inc.
-1.4%
-$13,000 
CRWD CrowdStrike Holdings, Inc.
-1.26%
-$201,402.02 
AMZN Amazon.com Inc
-1.23%
-$138,056.89 
BCYC Bicycle Therapeutics plc American Depositary Receipt
-1.22%
-$78,044.1 
ENGN enGene Therapeutics Inc.
-1.22%
-$105,063.18 
SRRK Scholar Rock Holding Corporation
-1.14%
-$5.52M 
SLDB Solid Biosciences Inc.
-1.11%
-$615,232.4 
FROG JFrog Ltd
-0.94%
-$95,323.84 
AVGO Broadcom Inc.
-0.91%
-$52,500.04 
NOW ServiceNow, Inc.
-0.9%
-$80,993.87 
GPCR Structure Therapeutics Inc.
-0.85%
-$491,618.26 
KLRS Kalaris Therapeutics, Inc.
-0.69%
-$13,073.94 
WK Workiva Inc.
-0.41%
-$18,500 
AS Amer Sports, Inc.
-0.39%
-$7,000 
SION Sionna Therapeutics Inc.
-0.36%
-$38,999.7 
IONQ IonQ, Inc.
-0.24%
-$23,800 
XENE Xenon Pharmaceuticals Inc.
-0.17%
-$118,673.4 
IRON Disc Medicine Inc.
-0.13%
-$88,958.07 
CNTA Centessa Pharmaceuticals plc American Depositary Receipt
-0.13%
-$52,673.2 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 536 | Longs Won 239/536 44% | Profit Factor 2.79 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $18.18M |
| Average Win $7.58M | Best Trade (Jun 14) $334.57M | Sharpe Ratio -10.32 |
| Average Loss -$2.19M | Worst Trade (Sep 29) -$50.2M | Z-Score 2.07 (96.14%) |
| Commissions $0 | Avg. Trade Length 8m 3w 6d | Expectancy $2.31M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.56% |
| Consecutive Losing Trades | 1,613 | 1,452 | 1,290 | 1,129 | 968 | 806 | 645 | 484 | 323 | 161 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
